Bank of New York Mellon Corp cut its position in shares of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) by 0.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 306,563 shares of the biotechnology company’s stock after selling 552 shares during the period. Bank of New York Mellon Corp owned approximately 0.42% of BioCryst Pharmaceuticals worth $870,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently made changes to their positions in BCRX. Goldman Sachs Group Inc. raised its position in shares of BioCryst Pharmaceuticals by 11.8% in the first quarter. Goldman Sachs Group Inc. now owns 1,237,418 shares of the biotechnology company’s stock worth $3,502,000 after buying an additional 130,133 shares during the period. Royce & Associates LP acquired a new stake in BioCryst Pharmaceuticals during the first quarter worth about $453,000. HBK Investments L P increased its stake in BioCryst Pharmaceuticals by 152.7% in the first quarter. HBK Investments L P now owns 49,773 shares of the biotechnology company’s stock worth $141,000 after buying an additional 30,073 shares in the last quarter. Amici Capital LLC acquired a new stake in BioCryst Pharmaceuticals during the first quarter worth about $283,000. Finally, Quantitative Systematic Strategies LLC acquired a new stake in BioCryst Pharmaceuticals during the second quarter worth about $186,000. Institutional investors and hedge funds own 70.32% of the company’s stock.
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) traded up 2.26% during trading on Tuesday, reaching $4.08. 69,730 shares of the company were exchanged. BioCryst Pharmaceuticals Inc. has a one year low of $1.63 and a one year high of $10.98. The company’s market capitalization is $300.70 million. The firm’s 50-day moving average is $4.41 and its 200 day moving average is $3.61.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.04. BioCryst Pharmaceuticals had a negative net margin of 285.24% and a negative return on equity of 187.98%. The business earned $4.80 million during the quarter, compared to the consensus estimate of $3.92 million. During the same quarter last year, the company posted $0.06 earnings per share. The firm’s quarterly revenue was down 81.4% compared to the same quarter last year. On average, analysts anticipate that BioCryst Pharmaceuticals Inc. will post ($1.03) EPS for the current fiscal year.
BCRX has been the subject of a number of recent research reports. FBR & Co reissued a “buy” rating and issued a $6.00 price objective on shares of BioCryst Pharmaceuticals in a report on Wednesday, July 6th. HC Wainwright reissued a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Friday, August 5th. JPMorgan Chase & Co. reissued a “hold” rating on shares of BioCryst Pharmaceuticals in a report on Friday, August 5th. Jefferies Group boosted their price objective on shares of BioCryst Pharmaceuticals from $2.00 to $3.00 and gave the company a “hold” rating in a report on Friday, August 5th. Finally, JMP Securities downgraded shares of BioCryst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, August 4th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the company’s stock. BioCryst Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $8.22.
In other news, VP Alane P. Barnes sold 8,357 shares of BioCryst Pharmaceuticals stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $4.27, for a total value of $35,684.39. Following the completion of the transaction, the vice president now owns 79,377 shares in the company, valued at $338,939.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Bros. Advisors Lp Baker sold 4,046,590 shares of BioCryst Pharmaceuticals stock in a transaction dated Tuesday, August 16th. The stock was sold at an average price of $5.00, for a total transaction of $20,232,950.00. The disclosure for this sale can be found here. Corporate insiders own 5.80% of the company’s stock.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.